342 related articles for article (PubMed ID: 31639216)
1. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
2. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
Inaguma S; Ueki A; Lasota J; Komura M; Sheema AN; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Miettinen M; Takahashi S
J Pathol Clin Res; 2023 May; 9(3):195-207. PubMed ID: 36754859
[TBL] [Abstract][Full Text] [Related]
3. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
4. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
5. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
6. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
Ahmadzada T; Lee K; Clarke C; Cooper WA; Linton A; McCaughan B; Asher R; Clarke S; Reid G; Kao S
Lung Cancer; 2019 Apr; 130():35-41. PubMed ID: 30885349
[TBL] [Abstract][Full Text] [Related]
7. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.
Tazzari M; Brich S; Tuccitto A; Bozzi F; Beretta V; Spagnuolo RD; Negri T; Stacchiotti S; Deraco M; Baratti D; Camisaschi C; Villa A; Vergani B; Rivoltini L; Pilotti S; Castelli C
J Immunol Res; 2018; 2018():5804230. PubMed ID: 30510965
[TBL] [Abstract][Full Text] [Related]
8. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
10. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
11. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
12. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
Cornelissen R; Lievense LA; Maat AP; Hendriks RW; Hoogsteden HC; Bogers AJ; Hegmans JP; Aerts JG
PLoS One; 2014; 9(9):e106742. PubMed ID: 25192022
[TBL] [Abstract][Full Text] [Related]
13. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
14. CD70 expression in tumor-associated fibroblasts predicts worse survival in colorectal cancer patients.
Inoue S; Ito H; Tsunoda T; Murakami H; Ebi M; Ogasawara N; Kasugai K; Kasai K; Ikeda H; Inaguma S
Virchows Arch; 2019 Oct; 475(4):425-434. PubMed ID: 30980190
[TBL] [Abstract][Full Text] [Related]
15. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
16. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E
Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741
[TBL] [Abstract][Full Text] [Related]
17. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
18. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
[TBL] [Abstract][Full Text] [Related]
19. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
Yamada N; Oizumi S; Kikuchi E; Shinagawa N; Konishi-Sakakibara J; Ishimine A; Aoe K; Gemba K; Kishimoto T; Torigoe T; Nishimura M
Cancer Immunol Immunother; 2010 Oct; 59(10):1543-9. PubMed ID: 20567822
[TBL] [Abstract][Full Text] [Related]
20. Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.
De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Rottey S; Ferdinande L
Pathology; 2017 Jun; 49(4):397-404. PubMed ID: 28427753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
